A large American study has quietly redrawn the map of diabetes care, revealing that not all kidneys face the same threat — nor benefit from the same shield. Researchers tracking more than 75,000 patients found that GLP-1 receptor agonists and SGLT-2 inhibitors meaningfully slow kidney decline, but only in those whose urine already carries excess protein, a marker known as albuminuria. The finding is less a discovery of a new drug's power than a reminder of an older medical truth: the right medicine depends on knowing which patient you are treating.
GLP-1 and SGLT-2 drugs slow kidney decline in diabetics with protein in urine
Kidney protection depends on whether patients have protein in their urine
Mark
So the headline is that these two drug classes protect kidneys in diabetics. But it sounds like that's only true for some patients?
Mimi
Exactly. The protection is real and substantial—40 percent lower risk of kidney decline—but only in patients who already have albuminuria, which is protein in the urine. That's about 18 percent of the study population.
Luke
And for the 82 percent without albuminuria, what did they find?
Mimi
Little to no kidney benefit from GLP-1 or SGLT-2 drugs over the study period. The risks were low across the board in that group, but there wasn't a meaningful difference between the drug classes.
Mark
That seems like an important distinction that could get lost in the headlines.
Mimi
It absolutely could. And there's another wrinkle: sulfonylureas actually showed a 31 percent increased risk of kidney decline in the non-albuminuria group, which is the opposite of what you'd expect if you only read the lede.
Luke
How confident should we be in these numbers? What are the caveats?
Mimi
The researchers are pretty transparent. The follow-up was only 32 months on average, which is short for kidney disease. And they're using observational data, not a randomized trial, so there could be unmeasured factors at play.
Luke
Like what?
Mimi
Lifestyle factors, diet, other medications not captured in the claims data, severity of diabetes itself. The study can't rule those out.
Mark
So the takeaway for doctors is what, exactly?
Mimi
Check whether your patient has albuminuria before choosing between these drugs. If they do, GLP-1 or SGLT-2 inhibitors look like the better choice for kidney protection. If they don't, the kidney benefit isn't clear yet.
Il Polso
- Two of the most celebrated drug classes in modern diabetes care — GLP-1 receptor agonists and SGLT-2 inhibitors — cut the five-year risk of kidney deterioration by 40% in diabetics with albuminuria, a gap too large to ignore in clinical practice.
- For the majority of patients in the study — those without albuminuria — the kidney-protective advantage of these drugs largely evaporated, exposing a fault line between how these medications are popularly perceived and how they actually perform across different patient profiles.
- Sulfonylureas, still widely prescribed, carried a 31% higher risk of kidney decline in patients without albuminuria compared to DPP-4 inhibitors, raising urgent questions about whether millions of patients are on medications that quietly work against their kidneys.
- The study's 32-month average follow-up and observational design leave room for uncertainty, but its scale — 75,455 patients, eight years of data — gives its conclusions considerable weight in an ongoing debate about personalized diabetes treatment.
- The trajectory is toward a more stratified approach to prescribing: albuminuria status emerging not as a footnote in a patient's chart, but as a primary signal guiding which drug a person with type 2 diabetes should receive.
A large American study has quietly redrawn the map of diabetes care, revealing that not all kidneys face the same threat — nor benefit from the same shield. Researchers tracking more than 75,000 patients found that GLP-1 receptor agonists and SGLT-2 inhibitors meaningfully slow kidney decline, but only in those whose urine already carries excess protein, a marker known as albuminuria. The finding is less a discovery of a new drug's power than a reminder of an older medical truth: the right medicine depends on knowing which patient you are treating.
A study published in The BMJ has found that two widely used diabetes drug classes — GLP-1 receptor agonists and SGLT-2 inhibitors — slow kidney function decline in type 2 diabetes patients, but with an important caveat: the benefit appears concentrated in those who have albuminuria, a condition in which excess protein leaks into the urine and signals early kidney stress.
The research drew on health records and insurance claims for more than 75,000 American adults with type 2 diabetes at moderate cardiovascular risk, tracking them for an average of nearly three years. Among the roughly 14,000 patients with albuminuria, those on GLP-1 or SGLT-2 drugs faced a five-year kidney decline risk of 3.2%, compared to 5.4% for those on DPP-4 inhibitors — a 40% relative reduction that points to a meaningful protective effect for this subgroup.
The story shifted for the more than 61,000 patients without albuminuria. Here, the kidney-protective edge of GLP-1 and SGLT-2 drugs largely disappeared, and DPP-4 inhibitors performed comparably or better. More strikingly, sulfonylureas — a long-established and widely prescribed class — were associated with a 31% higher risk of kidney decline in this group, a finding that complicates their continued use without careful patient selection.
Prior research had suggested these newer drugs might benefit kidneys more in patients with higher protein levels in their urine, but this study offers a clearer answer: the renal protection is real, but it is not universal. The researchers used target trial emulation, a rigorous method for drawing causal inferences from observational data, while acknowledging that a 32-month follow-up may be too short to capture the full arc of kidney disease progression.
The practical message for clinicians is pointed: albuminuria status should be a primary consideration when choosing diabetes medications, not an afterthought. As personalized medicine continues to reshape how chronic diseases are managed, this distinction between patient subgroups may ultimately influence the treatment paths of millions.
A large study of American diabetes patients has found that two widely prescribed drug classes—GLP-1 receptor agonists and SGLT-2 inhibitors—appear to slow the decline of kidney function in people with type 2 diabetes who have albuminuria, a condition marked by excess protein in the urine. The research, published in The BMJ, analyzed health records and insurance claims for 75,455 individuals with type 2 diabetes at moderate cardiovascular risk who began treatment with one of four medication types between 2014 and 2022. The findings suggest that the kidney-protective effects of these drugs may depend heavily on whether a patient has albuminuria—a distinction that could reshape how doctors choose treatments.
The study tracked patients for an average of 32 months, measuring kidney function decline through blood tests. Among the 13,872 patients who had albuminuria at the start of the study, those taking GLP-1 receptor agonists or SGLT-2 inhibitors faced a five-year risk of kidney function decline of 3.2 percent. By comparison, patients on sulfonylureas faced a 4.6 percent risk, and those on DPP-4 inhibitors faced 5.4 percent. This translates to a 40 percent lower risk of kidney deterioration for patients on GLP-1 or SGLT-2 drugs compared to DPP-4 inhibitors—a substantial difference that underscores the potential benefit of these medications for a specific patient population.
But the picture shifted dramatically for the 61,583 patients without albuminuria. In this group, the five-year risk of kidney decline was 2.4 percent for those on GLP-1 or SGLT-2 drugs, 2.8 percent for sulfonylureas, and 2.1 percent for DPP-4 inhibitors. Notably, sulfonylureas showed a 31 percent increased risk of kidney decline compared to DPP-4 inhibitors in patients without albuminuria—a finding that contradicts the protective pattern seen in the albuminuria group and suggests that treatment decisions cannot be one-size-fits-all.
Previous research had already established that GLP-1 receptor agonists and SGLT-2 inhibitors can reduce the risk of chronic kidney disease progression in people with type 2 diabetes, with hints that the benefit might be stronger in patients with higher levels of albuminuria. What remained unclear was whether patients without albuminuria would experience the same degree of kidney protection. This study provides a direct answer: the kidney benefits appear concentrated in the albuminuria population, with little evidence of renal protection in those without the condition over the study's follow-up period.
The researchers acknowledge important limitations. The average follow-up of 32 months is relatively short for assessing kidney disease progression, and unmeasured factors not captured in the data may have influenced the results. The study used target trial emulation, described as one of the most rigorous approaches for analyzing observational data, though the authors caution that this method is not immune to bias. Still, they emphasize that the analysis drew on rich clinical data from a large US population and employed methods designed to minimize common sources of bias in observational research.
The implication for clinical practice is straightforward: albuminuria status should factor into medication selection for people with type 2 diabetes. For those with protein in their urine, GLP-1 receptor agonists and SGLT-2 inhibitors appear to offer meaningful kidney protection. For those without albuminuria, the choice between these drugs and alternatives like DPP-4 inhibitors may rest on other considerations, and sulfonylureas may carry a kidney-related disadvantage. As diabetes treatment becomes increasingly personalized, this distinction between patient subgroups could influence how millions of people are medicated.
Citazioni salienti
GLP-1 receptor agonists and SGLT-2 inhibitors reduce the risk of deterioration of renal function in people with albuminuria. Little evidence of renal benefit among people without albuminuria was observed over the study follow-up period.— Study authors, published in The BMJ
Vuoi la storia completa?
Leggi l'originale su News-Medical ↗
Health & Medicine